Current Status of Transcatheter Aortic Valve Implantation: A Systematic Review of Non-orthodox Deployment Strategies

Abstract

points included feasibility, safety, efficacy, and durability. Results: The current literature regarding TAVI is limited to observational studies. Overall procedural success rates ranged from 90% to 100%. The incidence of major adverse events included: 30-day mortality (0%-18%), major adverse cardiovascular and cerebral events ranged from 2% to 35% and the rate of postoperative multiple organ failure was 2% to 8%. There was statistically significant hemodynamic improvement demonstrated by postoperative echocardiography measurements with no significant deterioration up to 6 months postprocedure. Survival at 6 months ranged from 59% to 93%. Only 5 one study with long-term of transapical TAVI follow-up could reliably evaluate long-term survival of 58% at 3 years. Significance: TAVI has proven to be feasible and potentially an effective intervention for non-surgical patients with symptomatic aortic stenosis. Although short-term efficacy based on echocardiography has been promising, there is a paucity of data concerning long-term outcomes. The evolution of TAVI will be dependent on the development of a valid tool for estimating the surgical risk to define indications for surgical aortic valve replacement versus transcatheter aortic valve implantation.